BW
ASBP

Boaz Weinstein’s Aspire Biopharma ASBP Stock Holding History

Boaz Weinstein’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,669
Closed -$21M – 669
2023
Q1 		$21M Hold
1,669
– – 0.4% 50
2022
Q4 		$20.6M Buy
1,669
+30
+2% +$367K 0.28% 81
2022
Q3 		$19.9M Hold
1,639
– – 0.22% 107
2022
Q2 		$19.6M Buy
+1,639
New +$19.6M 0.23% 93

Other funds holding ASBP

PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Boaz Weinstein's ASBP Position: Q2 2023 in Review

Boaz Weinstein sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 1,669 shares — an estimated $21M sold.

Boaz Weinstein first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $21M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

  • Boaz Weinstein reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
  • Boaz Weinstein sold 1,669 Aspire Biopharma shares in Q2 2023, an estimated $21M.
  • Boaz Weinstein first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
  • Boaz Weinstein's Aspire Biopharma position peaked at $21M in Q1 2023.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Saba Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.